Sign In
Buy BIO
$304.83
-1.30 (-0.425%)
At Close: Jun 03, 2026
Bio-Rad Laboratories, Inc. (BIO) Q4 2025 Earnings Call Transcript
07:34pm, Thursday, 12'th Feb 2026
Bio-Rad Laboratories, Inc. (BIO) Q4 2025 Earnings Call Transcript
Bio-Rad Laboratories (BIO) Q4 Earnings Miss Estimates
06:35pm, Thursday, 12'th Feb 2026
Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.51 per share, missing the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.9 per share a year ago.
Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
04:15pm, Thursday, 12'th Feb 2026
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t
Allianz Asset Management GmbH Boosts Position in Bio-Rad Laboratories, Inc. $BIO
03:30am, Saturday, 07'th Feb 2026
Allianz Asset Management GmbH raised its holdings in Bio-Rad Laboratories, Inc. (NYSE: BIO) by 22.7% during the undefined quarter, according to its most recent disclosure with the Securities and Excha
Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026
08:30am, Thursday, 29'th Jan 2026
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for t
BIO-key EMEA Partners with Citadel Global to Expand India Presence & Accelerate Adoption of Identity Solutions in Support of EU–India trade agreement
BIO-key and Visualforma Awarded Contract to Secure Digital Identities for Large Municipality in Portugal
04:00am, Wednesday, 28'th Jan 2026
BKYI: BIO-key & Visualforma awarded contract to Secure digital identities for large municipality in Portugal, enabling modern efficient citizen serivces.
Campbell & CO Investment Adviser LLC Makes New Investment in Bio-Rad Laboratories, Inc. $BIO
03:51am, Thursday, 22'nd Jan 2026
Campbell and CO Investment Adviser LLC acquired a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE: BIO) in the undefined quarter, according to the company in its most recent 13F filing with th
Artisan Mid Cap Value Fund Q4 2025 Performance Discussion And Portfolio Activity
01:33pm, Wednesday, 21'st Jan 2026
Online travel agency Expedia, our top overall contributor in Q4, drove performance in the consumer discretionary sector. Our top performers in the energy and financials sectors were NOV, a provider of
Here's Why You Should Hold Bio-Rad Stock in Your Portfolio Now
09:06am, Wednesday, 21'st Jan 2026
BIO benefits from steady Clinical Diagnostics demand and international growth, but macro pressures and currency headwinds could cap near-term upside.
ATLANTIC CITY & HOLMDEL, NJ / ACCESS Newswire / January 13, 2026 / BIO-key® International, Inc. (NASDAQ:BKYI), a leading provider of biometric enabled Identity and Access Management SaaS solutions fo
Parnassus Value Equity Fund Exits Ball Corp, Impacting Portfolio by -2.01%
12:01pm, Monday, 12'th Jan 2026
Insights into Parnassus Value Equity Fund (Trades, Portfolio)'s Strategic Moves in Q4 2025 Parnassus Value Equity Fund (Trades, Portfolio) recently submitted i
Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 44th Annual Healthcare Conference
08:45am, Tuesday, 06'th Jan 2026
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chie
Bio-Rad Laboratories, Inc. (NYSE:BIO) Receives Average Rating of “Hold” from Brokerages
01:49am, Wednesday, 31'st Dec 2025
Shares of Bio-Rad Laboratories, Inc. (NYSE: BIO - Get Free Report) have been given a consensus rating of "Hold" by the six ratings firms that are presently covering the firm, MarketBeat Ratings report
Exchange Traded Concepts LLC Buys 7,648 Shares of Bio-Rad Laboratories, Inc. $BIO
04:08am, Wednesday, 24'th Dec 2025
Exchange Traded Concepts LLC lifted its position in Bio-Rad Laboratories, Inc. (NYSE: BIO) by 54.9% in the undefined quarter, according to its most recent 13F filing with the SEC. The institutional in
